Loading stock data…
$68.79+1.05 (+1.55%)
GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. in the Healthcare sector is trading at $68.79 with a market capitalization of $28.9B. Wall Street consensus targets $82.70 (20 analysts), implying a +20.2% move over the next 12 months. The stock is currently 23% below its 52-week high of $89.77, remaining 2.6% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $5.29B↑ | $5.13B↓ | $5.70B↑ | $5.14B↑ | $5.01B |
| Gross Profit | $2.18B↑ | $1.98B↓ | $2.26B↑ | $1.99B↑ | $1.98B |
| Operating Income | $738.00M↑ | $515.00M↓ | $827.00M↑ | $653.00M↑ | $652.00M |
| Net Income | $560.00M↑ | $389.00M↓ | $589.00M↑ | $446.00M↓ | $486.00M |
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internati...
Academic risk and quality models computed from GEHC's own filings and price history, not from analyst opinion.
Mixed: 4 of 9 fundamental-health tests pass, so profitability and balance-sheet trends disagree.
Altman Z below 1.81, the financial-distress band. This measures balance-sheet stress, not share-price direction.
Beneish M below the -1.78 flag threshold, so the earnings-manipulation model finds nothing unusual in the accruals and margin trends.
Share of earnings coming from accruals rather than cash. Higher values historically precede weaker future returns.
Hidden Markov model fitted to two years of returns, separating bull, bear and sideways states by their own drift and volatility.
GARCH(1,1) 30-day annualised forecast, below the current 39.9% reading.
Fama-French 5-factor market beta. The five factors explain 33% of this stock's return variance; the rest is idiosyncratic.
The stock’s own historical valuation anchor, which is a fairer comparison than a sector average for a company with a persistent premium or discount.
Model inputs as of 2026-10-13.